Literature DB >> 24018271

Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold.

Sandro Prato1, Yifan Zhan, Justine D Mintern, Jose A Villadangos.   

Abstract

Initiation of CTL responses against foreign pathogens also primes anti-self CTLs. Mechanisms of CTL inactivation inhibit anti-self CTLs to prevent tissue damage. These mechanisms are exploited by pathogens and tumors to evade the immune response, and present a major hurdle to adoptive CTL therapies. It is unclear whether CTL inactivation is Ag specific and, if so, which APCs are involved. Potential candidates include the target cells themselves, dendritic cells, myeloid-derived suppressor cells, and macrophages. In this study, we show that lymphoma-specific CTLs are rapidly deleted in an Ag-specific manner after adoptive transfer into lymphoma-bearing mice, and the surviving CTLs are functionally impaired. The only APCs responsible were the target cells directly presenting Ag, notwithstanding the presence of myeloid-derived suppressor cells, and CD8(+) dendritic cells cross-presenting tumor Ag. The capacity to inactivate CTLs critically depended on the number of tumor/target cells; small numbers of targets were readily killed, but a large number caused quick deletion and functional inactivation of the CTLs. Application of mild, noninflammatory, and nonlymphoablative chemotherapy to specifically reduce tumor burden before CTL injection prevented CTL deletion and inactivation and allowed eradication of tumor. Our results advocate the use of adoptive CTL therapy soon after mild chemotherapy. They also suggest a simple mechanism for Ag-specific impairment of anti-self CTLs in the face of an active anti-foreign CTL response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24018271     DOI: 10.4049/jimmunol.1300803

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  2B4-SAP signaling is required for the priming of naive CD8+ T cells by antigen-expressing B cells and B lymphoma cells.

Authors:  Yu-Hsuan Huang; Kevin Tsai; Sara Y Tan; Sohyeong Kang; Mandy L Ford; Kenneth W Harder; John J Priatel
Journal:  Oncoimmunology       Date:  2016-12-27       Impact factor: 8.110

2.  Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression.

Authors:  Jing Liao; Yan Luan; Zhenhua Ren; Xiaojuan Liu; Diyuan Xue; Hairong Xu; Zhichen Sun; Kaiting Yang; Hua Peng; Yang-Xin Fu
Journal:  Cancer Immunol Res       Date:  2017-05-22       Impact factor: 11.151

Review 3.  Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?

Authors:  Marian Nassef Kadry Naguib Roufaiel; James W Wells; Raymond J Steptoe
Journal:  Front Immunol       Date:  2015-06-02       Impact factor: 7.561

Review 4.  Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes.

Authors:  Samuel I Kim; Christopher R Cassella; Katelyn T Byrne
Journal:  Front Immunol       Date:  2021-02-01       Impact factor: 7.561

5.  Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy.

Authors:  Hoyoung M Maeng; Brittni N Moore; Hadi Bagheri; Seth M Steinberg; Jon Inglefield; Kim Dunham; Wei-Zen Wei; John C Morris; Masaki Terabe; Lee C England; Brenda Roberson; Douglas Rosing; Vandana Sachdev; Svetlana D Pack; Markku M Miettinen; Frederic G Barr; Louis M Weiner; Sandhya Panch; David F Stroncek; Lauren V Wood; Jay A Berzofsky
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

6.  A Specific CD44lo CD25lo Subpopulation of Regulatory T Cells Inhibits Anti-Leukemic Immune Response and Promotes the Progression in a Mouse Model of Chronic Lymphocytic Leukemia.

Authors:  Agnieszka Goral; Malgorzata Firczuk; Klaudyna Fidyt; Marta Sledz; Francesca Simoncello; Karolina Siudakowska; Giulia Pagano; Etienne Moussay; Jérôme Paggetti; Patrycja Nowakowska; Stefania Gobessi; Joanna Barankiewicz; Aleksander Salomon-Perzynski; Federica Benvenuti; Dimitar G Efremov; Przemyslaw Juszczynski; Ewa Lech-Maranda; Angelika Muchowicz
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.